RxDoctor Payments Data

Michael Barnett, MD

Psychiatry · Visalia, CANPI 1760565154

Payments from drug & device makers

$2,712in general payments, 2019–2025

Across 131 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$523
  • Teva Pharmaceuticals USA, Inc.$135
  • Alkermes, Inc.$110
  • Takeda Pharmaceuticals U.S.A., Inc.$91
  • Sunovion Pharmaceuticals Inc.$40
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$2,57795%
  • Education$1355%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,712 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$15,346
Medicare patients
54
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate66$237,597
Chlorpromazine Hcl381$227,762
FanaptIloperidone104$153,377
IngrezzaValbenazine Tosylate12$102,838
CaplytaLumateperone Tosylate48$87,822
Aripiprazole485$39,806
Lurasidone Hcl144$35,311
Clozapine242$26,223
Paliperidone ErPaliperidone51$19,573
VraylarCariprazine Hcl14$19,541
RexultiBrexpiprazole11$15,335
Divalproex Sodium ErDivalproex Sodium227$15,098
Quetiapine Fumarate435$14,525
Fluphenazine Hcl43$14,327
Olanzapine552$13,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Fanapt$1,731$153,377104 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$523$87,82248 claims
AbbVieVraylar$14$19,54114 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$15,33511 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$91$10,01515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →